Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
Ikena, Senti and others look to clinical presentations at AACR.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
